Intellia 2025 Q1 Earnings Beats Expectations with EPS Surprise

Intellia Therapeutics, Inc. (NTLA) reported its fiscal 2025 Q1 earnings on May 8th, 2025. Intellia Therapeutics exceeded expectations with a quarterly loss of $1.10 per share, outperforming the Zacks Consensus Estimate of a loss of $1.26. This represents a 12.70% earnings surprise. The company also adjusted its guidance, projecting to complete enrollment in its global Phase 3 HAELO study by Q3 2025. With strategic advancements, Intellia aims to transform late-stage programs into commercial-ready offerings by the end of 2026.

Revenue

Intellia's total revenue for Q1 2025 decreased by 42.5% to $16.63 million compared to $28.93 million in Q1 2024. Collaboration revenue contributed entirely to the total, reflecting a significant decline from the previous year primarily due to reduced earnings from the AvenCell agreement.

Earnings/Net Income

Intellia reported a narrowed loss of $1.10 per share in Q1 2025, a slight improvement from the $1.12 loss per share in Q1 2024. Despite this, the net loss expanded to $114.33 million, marking a 6.4% increase year-over-year. The EPS indicates a modest improvement in financial performance despite the increased net loss.

Price Action

The stock price of Intellia rose by 5.14% on the latest trading day, fell 4.17% over the past week, and surged 26.61% month-to-date.

Post Earnings Price Action Review

Over the past five years, purchasing Intellia shares post revenue increase and holding them for 30 days yielded no returns. The strategy's performance was stagnant, with a 0.00% return, considerably underperforming the benchmark's 92.56% return. The excess return of -92.56% highlights the lack of profitability in this approach. Both the Sharpe ratio and maximum drawdown remained at 0.00%, underscoring the absence of risk and return from this strategy, indicating that investors might explore alternative strategies for better returns.

CEO Commentary

“Intellia is full steam ahead and making excellent progress across its clinical programs,” said John Leonard, M.D., President and CEO of Intellia Therapeutics. Key achievements in Q1 include dosing the first patients in two Phase 3 studies: the HAELO study for hereditary angioedema and the MAGNITUDE-2 study for hereditary ATTR amyloidosis with polyneuropathy. Enrollment in the MAGNITUDE study for ATTR with cardiomyopathy is progressing rapidly. Upcoming catalysts include longer-term data from the ongoing Phase 1 study of NTLA-2002 and updated data from the Phase 2 study of NTLA-2002 and Phase 1 data of nex-z in the second half of 2025.

Guidance

Intellia expects to complete enrollment in the global Phase 3 HAELO study by the third quarter of 2025 and aims to submit a Biologics License Application for NTLA-2002 in the second half of 2026. The company anticipates total enrollment in the MAGNITUDE trial will exceed 550 patients by year-end. Longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study is expected in the second half of 2025. Cash, cash equivalents, and marketable securities at the end of Q1 2025 were approximately $707.1 million, projected to fund operations into the first half of 2027.

Additional News

Intellia Therapeutics, Inc. announced strategic reorganization efforts earlier in the year, focusing resources on high-value programs NTLA-2002 and nex-z, leading to a workforce reduction of approximately 27% in 2025. The reorganization is expected to incur charges of about $8 million in Q1 2025, with anticipated cost savings helping to maintain a cash runway into the first half of 2027. Additionally, Laura Sepp-Lorenzino, Ph.D., Intellia’s Chief Scientific Officer, announced her retirement effective December 31, 2025, with Birgit Schultes, Ph.D., set to succeed her as Executive Vice President and Chief Scientific Officer, starting January 13, 2025.